CerTest Biotec Uses the BD MAX™ Molecular Diagnostic
System Open System Reagent Suite to Develop RT-PCR Detection
Kit
ZARAGOZA,
Spain and FRANKLIN LAKES, N.J., June 8, 2022
/PRNewswire/ -- CerTest Biotec and BD (Becton, Dickinson and
Company) (NYSE: BDX), a leading global medical technology company,
today announced a collaboration to develop a molecular diagnostic
test for the Monkeypox virus.
As part of the collaboration, the assay will leverage the BD
MAX™ open system reagent suite to validate the CerTest VIASURE
Monkeypox CE/IVD molecular test on the BD MAX™ System. The assay
will be available for BD MAX™ users and may help advance
understanding of the global spread of the disease.
"Enabling labs to rapidly respond to unexpected challenges is
the kind of evolving health care situations for which the BD MAX™
open system reagent suite is designed," said Nikos Pavlidis, vice president of Molecular
Diagnostics at BD. "Through our collaboration with CerTest and
their ability to rapidly transfer assays on the BD MAX™ System, we
will enable BD MAX™ System users around the world to access a test
for the confirmation of monkeypox."
The BD MAX™ System is a fully integrated, automated platform
that performs nucleic acid extraction and real-time PCR providing
results for up to 24 samples across multiple syndromes in less than
three hours. BD offers an extensive menu of tests on the system
covering healthcare associated infections, respiratory infections,
sexually transmitted infections, gastrointestinal infections, and
women's health diagnostics. BD offers a suite of open system
reagents for the BD MAX™ System that enables labs to fully automate
and streamline their Lab Developed Tests, and BD can partner with
customers to develop complementary assays on the system.
Nelson Fernandes, Managing
Director of CerTest BioTec, added "The strong capabilities of our
teams to rapidly develop molecular assays as well our experience
working with the BD MAX™ System enables us to accelerate the
development of an assay and further build our collaboration with
BD."
As with all CerTest tests, the Monkeypox PCR Detection Kit for
the BD MAX™ System will be offered in a lyophilized format.
Accordingly, the test will come in a tube that snaps into the
test-specific position on the BD MAX™ ExK™ TNA extraction
strip, which is supplied by BD.
About CerTest
CerTest Biotec is a European company established in 2002 for
the development and manufacturing of in vitro diagnostic medical
devices.
Today, CerTest is a global company structured around 7
business units offering one of the widest portfolios for human In
Vitro Diagnostic and Pharma. The company bases its future on a
strong technical knowledge and expertise in the detection of human
diseases.
CerTest last generation laboratories,
state-of-the-art technical equipment and skilled professionals are
the keys for providing reliable solutions for the medical
diagnostic professional.
About BD
BD is one of the largest global medical
technology companies in the world and is advancing the world of
health by improving medical discovery, diagnostics andbecton the
delivery of care. The company supports the heroes on the frontlines
of health care by developing innovative technology, services and
solutions that help advance both clinical therapy for patients and
clinical process for health care providers. BD and its 75,000
employees have a passion and commitment to help enhance the safety
and efficiency of clinicians' care delivery process, enable
laboratory scientists to accurately detect disease and advance
researchers' capabilities to develop the next generation of
diagnostics and therapeutics. BD has a presence in virtually every
country and partners with organizations around the world to address
some of the most challenging global health issues. By working in
close collaboration with customers, BD can help enhance outcomes,
lower costs, increase efficiencies, improve safety and expand
access to health care. For more information on BD, please visit
bd.com or connect with us on LinkedIn at
www.linkedin.com/company/bd1/ and Twitter @BDandCo.
Contacts:
|
|
|
|
Natalia
Bertran
|
|
Molecular Diagnostic
Manager
|
|
(+34) 976 520
354
|
|
viasure@certest.es
|
|
|
|
Media:
|
Investors:
|
Troy Kirkpatrick
|
Francesca
DeMartino
|
VP, Public Relations
|
SVP, Head of Investor
Relations
|
858.617.2361
|
201.847.5743
|
troy.kirkpatrick@bd.com
|
francesca.demartino@bd.com
|
*BD and BD MAX trademarks are property of BD (Becton, Dickinson
and Company).
*VIASURE is a registered trademark of CerTest Biotec,
S.L.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/certest-biotec-and-bd-announce-collaboration-on-molecular-diagnostic-test-for-monkeypox-301563444.html
SOURCE BD (Becton, Dickinson and Company)